Litcius/Paper detail

Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system

Donald C. Moore, Joseph B. Elmes, Justin Arnall, Scott A. Strassels, Jai N. Patel

2022International Immunopharmacology21 citationsDOI

Topics & Concepts

MedicinePembrolizumabAdverse Event Reporting SystemNivolumabAtezolizumabAdverse effectPharmacovigilanceThrombocytopenic purpuraInternal medicineOdds ratioThrombotic thrombocytopenic purpuraImmunologyCancerImmune systemImmunotherapyPlateletComplement system in diseasesBlood groups and transfusionPlatelet Disorders and Treatments
Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system | Litcius